Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBC-Ab002 in Early Alzheimer's Disease
NCT05551741Phase 1Completed
- Sponsor
- ImmunoBrain Checkpoint
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of IBC-Ab002 in Alzheimer's disease (AD) (5 cohorts), sponsored by ImmunoBrain Checkpoint. Primary endpoints: Number of Subjects With Adverse Events, Serious Adverse Events at 48 weeks, Number of Subjects With Clinically Significant Changes in Hematology Parameters at 48 weeks and 7 more. Started Mar 2023; status: completed.
02
Drugs
IBC-Ab002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05551741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05551741.